Human trials of its swine flu vaccine have begun, says GlaxoSmithKline.
The company plans to conduct 16 clinical trials of the vaccine in more than 9,000 people in Europe, Canada and the United States. Early results from the first trial in Germany are expected to be available in September, the Associated Press reported.
The findings will be shown to drug regulatory agencies in order to hasten their decisions about whether to approve the vaccine. Fast-track approval systems for swine flu vaccines have been created in Europe and the United States.
Earlier this month, Novartis and Sanofi-aventis began testing their swine flu vaccines, the AP reported. – (HealthDay News, August 2009)